Eli Lilly and Company $LLY Shares Sold by CenterBook Partners LP

CenterBook Partners LP reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 62.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,749 shares of the company’s stock after selling 14,386 shares during the quarter. CenterBook Partners LP’s holdings in Eli Lilly and Company were worth $10,123,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Marshall & Sterling Wealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after buying an additional 15 shares during the last quarter. Torren Management LLC grew its position in shares of Eli Lilly and Company by 357.1% in the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after buying an additional 25 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $42,000. Foresight Capital Management Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $49,000. Finally, Caitlin John LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at approximately $64,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $17,020,770 over the last ninety days. 0.14% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on LLY. Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price for the company in a research note on Tuesday, September 15th. Bank of America reaffirmed a “buy” rating and set a $1,497.00 price target on shares of Eli Lilly and Company in a research report on Friday, October 30th. UBS Group raised their price objective on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Guggenheim boosted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Finally, Truist Financial restated a “buy” rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,404.14.

Eli Lilly and Company Stock Performance

LLY stock traded up $7.42 during trading on Friday, reaching $1,372.15. The company had a trading volume of 3,802,992 shares, compared to its average volume of 2,624,130. The company has a market cap of $1.29 trillion, a price-to-earnings ratio of 44.54, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm has a 50-day simple moving average of $1,215.24 and a 200-day simple moving average of $1,101.16.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $7.02 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is 22.46%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.